Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348883 | 0.82 | CNR1 (0.60) | CNR1MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL10192080 | 0.82 | ALDH1A1 (0.64) | CNR1EPHX1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4624732 | 0.82 | FOLH1 (0.52) | CNR1HDAC1HDAC6EPHX1MAPT | |
| SCHEMBL2234743 | 0.81 | EPHX1 (0.68) | CNR1HDAC1HDAC6EPHX1KDM4E | |
| SCHEMBL17841795 | 0.81 | EPHX1 (0.70) | HDAC1EPHX1MAPTLMNAALDH1A1 | |
| SCHEMBL18843562 | 0.78 | HDAC1 (0.57) | HDAC1HDAC6EPHX1MAPTKDM4E | |
| SCHEMBL6689486 | 0.78 | CNR1 (0.59) | CNR1EPHX1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL20681685 | 0.78 | MEN1 (0.68) | CNR1LMNAKMT2ASMN1; SMN2HTT | |
| SCHEMBL10642896 | 0.78 | CNR1 (0.63) | CNR1EPHX1MAPTKDM4ELMNA | |
| SCHEMBL13724331 | 0.78 | GHSR (0.51) | CNR1EPHX1KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-112888696-B | Exonuclease inhibitors and methods of use thereof | 德琪医疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-112888696-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3810617-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR1 254/4885HDAC1 3062/4885HDAC6 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.